<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4342">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03050398</url>
  </required_header>
  <id_info>
    <org_study_id>CLEE011AUS42</org_study_id>
    <nct_id>NCT03050398</nct_id>
  </id_info>
  <brief_title>A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib</brief_title>
  <official_title>A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will allow for the collection of tumor tissue samples to better understand
      relevant mutations and the mechanisms responsible for resistance to treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol is a sub-protocol of an interventional study. Because the main study is
      interventional, this study was approved by FDA as an interventional study. It cannot stand
      alone without the parent study. The sites will receive diagnostic information for all
      patients that come on study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 15, 2017</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with change in mutation between baseline and time of progression to determine the modes of resistance to ribociclib utilizing tissue samples</measure>
    <time_frame>Baseline, time of progression approximately 24 months</time_frame>
    <description>Mutations of genes that are relevant to HR+ and the CDK4/6 pathway such as but not limited to CCND1, CDKN2A, PIK3CA and PTEN to identify the potential mechanisms of progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of mutations by ethnic groups</measure>
    <time_frame>Baseline</time_frame>
    <description>Differences in mutations will be assessed based on baseline samples and compared across diverse races/ethnicities with HR+ HER2- advanced breast cancer - specifically Caucasian, African America, Hispanic, Native American and Pacific Islander.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>ribociclib + letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ribociclib with letrozole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <description>ribociclib + letrozole</description>
    <arm_group_label>ribociclib + letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>letrozole</intervention_name>
    <description>ribociclib + letrozole</description>
    <arm_group_label>ribociclib + letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent must be obtained prior to any baseline/screening procedures.

          -  Patients eligible for this companion sample collection protocol sample collection
             protocol must meet all inclusion in CLEE011A2404.

        Exclusion Criteria:

          -  Patients eligible for this companion sample collection protocol must not meet any of
             the exclusion criteria in the CLEE011A2404 study, in addition to the following:

          -  Patients without either fresh or archival tumor tissue accessible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
  </overall_contact_backup>
  <verification_date>April 2017</verification_date>
  <lastchanged_date>April 7, 2017</lastchanged_date>
  <firstreceived_date>February 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HR-positive</keyword>
  <keyword>HER2-negative</keyword>
  <keyword>Advanced breast cancer</keyword>
  <keyword>LEE011</keyword>
  <keyword>ribociclib</keyword>
  <keyword>letrozole</keyword>
  <keyword>femara</keyword>
  <keyword>CDK</keyword>
  <keyword>CDK4</keyword>
  <keyword>CDK6</keyword>
  <keyword>CDK4/6</keyword>
  <keyword>CDK4/6 inhibitor</keyword>
  <keyword>Phase III</keyword>
  <keyword>Phase IIIb</keyword>
  <keyword>ER-positive</keyword>
  <keyword>PR-positive</keyword>
  <keyword>Postmenopausal</keyword>
  <keyword>Premenopausal</keyword>
  <keyword>Men</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Letrozole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
